Article    Table of Contents                    Full Text of this article Free    Figures/Tables List  Services    Send comment/rapid response letter    Notify a friend about this article    Alert me when this article is cited    Add to Personal Archive    Download to Citation Manager    ACP Search                            Get Permissions  Google Scholar    Search for Related Content  PubMed Articles in PubMed by Author:    Singh, N.    Carrigan, D. R.    Related Articles in PubMed    PubMed Citation    PubMed

REVIEW

Human Herpesvirus-6 in Transplantation: An Emerging Pathogen

Nina Singh, MD, and Donald R. Carrigan, PhD

15 June 1996 | Volume 124 Issue 12 | Pages 1065-1071

Background: Human herpesvirus-6 can be an opportunistic pathogen in transplant recipients.

Purpose: To summarize the epidemiologic and clinical aspects of human herpesvirus-6 infection, the immunologic basis of the pathogenicity of human herpesvirus-6, and the management of human herpesvirus-6 infection in transplant recipients.

Data Sources: English-language articles identified through a MEDLINE search from 1986 (when human herpesvirus-6 was discovered) to the present, bibliographies of identified articles, and recognized texts.

Study Selection: Reports on human herpesvirus-6 infections in bone marrow transplant recipients and in solid organ transplant recipients.

Data Extraction: Data on the virology, detection, epidemiology, clinical features, and treatment of human herpesvirus-6 infection were manually abstracted from the indicated sources and summarized. Data quality and validity were independently assessed by both authors.

Data Synthesis: Human herpesvirus-6 infection occurred in 38% to 60% of bone marrow transplant recipients and 31% to 55% of solid organ transplant recipients, usually 2 to 4 weeks after transplantation. Human herpesvirus-6 has two variants, designated variant A and variant B; transplant recipients were infected almost exclusively with variant B. Bone marrow suppression, interstitial pneumonitis, and encephalitis were the most commonly reported types of clinical disease caused by human herpesvirus-6. The marrow-suppressive effect of human herpesvirus-6 ranged from transient or self-limited bone marrow suppression to chronic or fatal aplastic anemia; bone marrow suppression was thought to be partially cytokine-mediated. Because it can depress cell-mediated immunity, human herpesvirus-6 may facilitate superinfection by other pathogens. Human herpesvirus-6 resembles cytomegalovirus in its antiviral susceptibilities: It is resistant to acyclovir but susceptible to ganciclovir and foscarnet. Prophylaxis of human herpesvirus-6 infection is feasible in transplant recipients, but this issue must be studied further.

Conclusion: Human herpesvirus-6 can be a pathogen in transplant recipients. Prompt recognition of disease associated with human herpesvirus-6 is important because this virus is susceptible to currently available antiviral agents. Future research should focus on delineating the complete clinical spectrum, immunologic sequelae, and efficacy of prophylactic strategies for human herpesvirus-6 infection in transplant recipients.

Author and Article Information

From the Veterans Affairs Medical Center, Pittsburgh, Pennsylvania, and the Medical College of Wisconsin, Milwaukee, Wisconsin.
Requests for Reprints: Nina Singh, MD, Veterans Affairs Medical Center, Infectious Disease Section, University Drive C, Pittsburgh, PA 15240.
Current Author Addresses: Dr. Singh: Veterans Affairs Medical Center, Infectious Disease Section, University Drive C, Pittsburgh, PA 15240.

This article has been cited by other articles:

				B. C. Weikert and E. A. Blumberg Viral Infection after Renal Transplantation: Surveillance and Management Clin. J. Am. Soc. Nephrol., March 1, 2008; 3(Supplement_2): S76 - S86. [Abstract] [Full Text] [PDF]

				C. N. Kotton and J. A. Fishman Viral Infection in the Renal Transplant Recipient J. Am. Soc. Nephrol., June 1, 2005; 16(6): 1758 - 1774. [Abstract] [Full Text] [PDF]

				M. L. Opsahl and P. G. E. Kennedy Early and late HHV-6 gene transcripts in multiple sclerosis lesions and normal appearing white matter Brain, March 1, 2005; 128(3): 516 - 527. [Abstract] [Full Text] [PDF]

				G. A. E. Wong and N. H. Shear Is a Drug Alone Sufficient to Cause the Drug Hypersensitivity Syndrome? Arch Dermatol, February 1, 2004; 140(2): 226 - 230. [Full Text] [PDF]

				F. J. Jenkins, D. T. Rowe, and C. R. Rinaldo Jr. Herpesvirus Infections in Organ Transplant Recipients Clin. Vaccine Immunol., January 1, 2003; 10(1): 1 - 7. [Full Text] [PDF]

				D.H. Dockrell Human herpesvirus 6: molecular biology and clinical features J. Med. Microbiol., January 1, 2003; 52(1): 5 - 18. [Abstract] [Full Text] [PDF]

				L. De Bolle, D. Michel, T. Mertens, C. Manichanh, H. Agut, E. De Clercq, and L. Naesens Role of the Human Herpesvirus 6 U69-Encoded Kinase in the Phosphorylation of Ganciclovir Mol. Pharmacol., September 1, 2002; 62(3): 714 - 721. [Abstract] [Full Text] [PDF]

				J. Sashihara, K. Tanaka-Taya, S. Tanaka, K. Amo, H. Miyagawa, G. Hosoi, T. Taniguchi, T. Fukui, N. Kasuga, T. Aono, et al. High incidence of human herpesvirus 6 infection with a high viral load in cord blood stem cell transplant recipients Blood, August 28, 2002; 100(6): 2005 - 2011. [Abstract] [Full Text] [PDF]

				A. M. Kearns, A. J. L. Turner, C. E. Taylor, P. W. George, R. Freeman, and A. R. Gennery LightCycler-Based Quantitative PCR for Rapid Detection of Human Herpesvirus 6 DNA in Clinical Material J. Clin. Microbiol., August 1, 2001; 39(8): 3020 - 3021. [Full Text] [PDF]

				M. Luppi, P. Barozzi, T. F. Schulz, G. Setti, K. Staskus, R. Trovato, F. Narni, A. Donelli, A. Maiorana, R. Marasca, et al. Bone Marrow Failure Associated with Human Herpesvirus 8 Infection after Transplantation N. Engl. J. Med., November 9, 2000; 343(19): 1378 - 1385. [Abstract] [Full Text] [PDF]

				Management of herpes virus infections following transplantation J. Antimicrob. Chemother., June 1, 2000; 45(6): 729 - 748. [Full Text] [PDF]

				P. Zou, Y. Isegawa, K. Nakano, M. Haque, Y. Horiguchi, and K. Yamanishi Human Herpesvirus 6 Open Reading Frame U83 Encodes a Functional Chemokine J. Virol., July 1, 1999; 73(7): 5926 - 5933. [Abstract] [Full Text]

				A. Ansari and V. C. Emery The U69 Gene of Human Herpesvirus 6 Encodes a Protein Kinase Which Can Confer Ganciclovir Sensitivity to Baculoviruses J. Virol., April 1, 1999; 73(4): 3284 - 3291. [Abstract] [Full Text]

				M. Luppi, P. Barozzi, C. Morris, A. Maiorana, R. Garber, G. Bonacorsi, A. Donelli, R. Marasca, A. Tabilio, and G. Torelli Human Herpesvirus 6 Latently Infects Early Bone Marrow Progenitors In Vivo J. Virol., January 1, 1999; 73(1): 754 - 759. [Abstract] [Full Text] [PDF]

				F. Drago and A. Rebora The New Herpesviruses: Emerging Pathogens of Dermatological Interest Arch Dermatol, January 1, 1999; 135(1): 71 - 75. [Abstract] [Full Text] [PDF]

				J. Gomez-Moreno, V. Cuervas-Mons, R. Ridzon, I. M. Onorato, S. M. Palmer, V. F. Tapson, A. M. Stamm, J. A. Fishman, and R. H. Rubin Infection in Organ-Transplant Recipients N. Engl. J. Med., October 22, 1998; 339(17): 1244 - 1246. [Full Text]

				M. Luppi, P. Barozzi, R. Garber, A. Maiorana, G. Bonacorsi, T. Artusi, R. Trovato, R. Marasca, and G. Torelli Expression of Human Herpesvirus-6 Antigens in Benign and Malignant Lymphoproliferative Diseases Am. J. Pathol., September 1, 1998; 153(3): 815 - 823. [Abstract] [Full Text] [PDF]

				Y. Suzuki, R. Inagi, T. Aono, K. Yamanishi, and T. Shiohara Human Herpesvirus 6 Infection as a Risk Factor for the Development of Severe Drug-Induced Hypersensitivity Syndrome Arch Dermatol, September 1, 1998; 134(9): 1108 - 1112. [Abstract] [Full Text] [PDF]

				P. Mirandola, P. Menegazzi, S. Merighi, T. Ravaioli, E. Cassai, and D. Di Luca Temporal Mapping of Transcripts in Herpesvirus 6 Variants J. Virol., May 1, 1998; 72(5): 3837 - 3844. [Abstract] [Full Text] [PDF]